Uveitis Treatment Market Size, Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027

Uveitis Treatment Market size is projected to experience significant growth from 2019 to 2025.
 

Growing prevalence of uveitis and rising issues associated with it such as blindness that causes due to uveitis is one of the major factors that is driving the growth of the uveitis treatment market. For instance, according to the Prevent Blindness organization, Uveitis causes around 30,000 new cases of blindness each year in the U.S. The upsurge in the development of biological drugs for the treatment of uveitis is driving the growth of the market and the growing demand for these drugs in the countries that have higher statistics of patients  affected with uveitis are further expected to witness the significant traction in the upcoming years.
 

The growing demand for the drugs such as corticosteroids and anti-inflammatory medications in order to treat uveitis in the developing countries is one of the factors that is fueling the growth of the market. For instance, according to an article published in the National Center for Biotechnology Information (NCBI) in 2013, Uveitis is the leading cause of blindness in the developing countries including India. Around 25% of blindness is attributed to uveitis and its complications that cause blindness are glaucoma, cataract, and, optic nerve damage etc.
 

Furthermore, according to the NCBI, in developed countries the incidence of blindness caused from uveitis fluctuates from 3% to 10%. For instance, in the U.S. the statistics of 2013 showed that the 10% of blindness caused due to uveitis was reported from California. The statistics further showed that, in Europe the incidence is projected to be between 3% and 7%. The cause of uveitis in developed countries is reported owing to be an organ specific immune inflammatory process. Whereas, the cause of blindness due to uveitis in developing countries is attributed to the infections. Thus, the growing awareness of proper etiologic diagnosis and treatment in developing countries such as India witness the lucrative growth of the uveitis treatment market over the forecast period.
 

Introduction of innovative biologics, growing number of research & development investments in drug discovery and development, increasing approval of pipeline drugs and significant rise in the government initiatives to curtail eye disorders caused due to uveitis is boosting the growth of the market. In addition, growing demand for generic drugs also prompt a trend in the uveitis treatment market that has further push the range of opportunities for new players in the market.
 

However, lack of primary healthcare infrastructure such as hospitals & clinics, unavailability of health insurance in developing countries may restrict the overall growth of the market in the future years.
 

Anterior uveitis is expected to witness the lucrative growth over the forecast period. This is attributed to the rising prevalence of chronic diseases such as rheumatoid arthritis, trauma to the eye, and mumps. Growing personal disposable income, rising expenditure in healthcare sector and favorable government regulation are some other major drivers of this market. 
 

Immunosuppressive medications segment is dominating the uveitis treatment market. This is attributed to the couple of factors such as growing demand for off label immune suppressive medications and biologics for the treatment of uveitis. Furthermore, easy accessibility to these drugs is also one of the factors for the growth of the market.
 

North America is currently dominating the uveitis treatment market in the region. This is attributed to the couple of factors such as growing geriatric population base, upsurge in the eye related disorders-particularly uveitis and rising investments in the research & development pertinent to uveitis and availability of medications.
 

Asia Pacific is expected to witness the lucrative growth over the forecast period. The countries like India, china is projected to witness the significant growth in the uveitis treatment market. This is attributed to the growing disposable income, and rising number of patients affected with uveitis.
 

Few of the key companies operating in uveitis treatment market include Bausch & Lomb, Novartis AG, EyeGate, Santen Pharmaceutical Co., Ltd, EyePoint Pharmaceuticals, ALLERGAN, Alimera Sciences, Regeneron Pharmaceuticals, Wize Pharma Inc., Enzo Biochem Inc., and Alcon Inc. key companies in the market are undergoing collaborations, partnerships and merger & acquisitions in order to expand their product portfolio. For instance, in 2016, Allergan, acquired a gene therapy company RetroSense therapeutics to augment the company's eye care product pipeline. Subsequently, Allergan launched an influential uveitis drug Taytulla.
 

Uveitis Treatment Market by Type, 2014-2025 (USD Million)

• Anterior uveitis
• Posterior uveitis
• Intermediate uveitis
• Panuveitis  

Uveitis Treatment Market by Treatment, 2014-2025 (USD Million)

• Immunosuppressive Medications
• Antibiotic/Antiviral Medications
• Anti-inflammatory Medications

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
• Latin America
  • Mexico
  • Brazil
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia

Company Profiles:

• Bausch & Lomb
• Novartis AG
• EyeGate
• Santen Pharmaceutical Co., Ltd.
• EyePoint Pharmaceuticals
• ALLERGAN
• Alimera Sciences
• Regeneron Pharmaceuticals
• Wize Pharma Inc.
• Enzo Biochem Inc.
• Alcon Inc.

What Information does this report contain?